Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment Webcast (2021)

Treatment of renal cell carcinoma has changed with expanding indications for Robotic Partial nephrectomy and inclusion of new FDA approved treatments  for advanced RCC.  This course will focus on didactic case discussions using video tape analysis of surgical treatment, setup and successful completion of Robotic Partial nephrectomy, complication management and how to optimize outcomes.  Urologists are now faced with treatment of advanced RCC with a host of options, from tyrosine kinase inhibitors to checkpoint inhibitors.  There will be discussion focus on how to monitor, and algorithms for when to switch treatment.

ACKNOWLEDGEMENTS

Independent educational grant support provided by: 

  • AstraZeneca
  • Bristol-Myers Squibb
  • Merck   

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. Manage bleeding complications of robotic partial nephrectomy
  2. Describe the algorithm of Immunotherapy treatment of advanced Renal Cell Carcinoma
  3. Minimize positive margin rates of robotic partial nephrectomy
     
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
09/15/2021
Course expires: 
09/15/2022
Rating: 
0

Education Council Disclosures

 Education Council Disclosures 2021

COI Review Work Group Disclosures

 COI Review Work Group Disclosures 2021

All relevant financial relationships have been mitigated. 

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Benjamin Lee, MD

has no relevant financial relationships to disclose at this time.
Faculty(s)

A. Oliver Sartor, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Fusion;.
has a financial relationship (Consultant or Advisor (General Urology)) with Myovant;.
has a financial relationship (Consultant or Advisor (General Urology)) with Constellation;.
has a financial relationship (Consultant or Advisor (General Urology)) with Bristol Myers Squibb;.
has a financial relationship (Consultant or Advisor (General Urology)) with Bavarian Nordic;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Astellas;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Advancel Accelerator Applications (AAA);.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with AstraZeneca;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with EMD Serono;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Bayer;.
has a financial relationship (Consultant or Advisor (Oncology)) with POINT Biopharma;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clarity Pharmaceuticals;.
has a financial relationship (Consultant or Advisor (General Urology)) with Myriad;.
has a financial relationship (Consultant or Advisor (General Urology)) with Clovis;.
has a financial relationship (Consultant or Advisor (General Urology)) with Novartis;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Progenics;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Invitae;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Endocyte;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tenebio;.
has a financial relationship (Consultant or Advisor (Oncology)) with Isotopen Technologien Meunchen;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Constellation;.
has a financial relationship (Consultant or Advisor (General Urology)) with Noxopharm;.
has a financial relationship (Consultant or Advisor (General Urology)) with Constellation;.
has a financial relationship (Consultant or Advisor (General Urology)) with Bristol Myers Squibb;.
has a financial relationship (Consultant or Advisor (General Urology)) with Bavarian Nordic;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Astellas;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Advancel Accelerator Applications (AAA);.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with AstraZeneca;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with EMD Serono;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Bayer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Telix;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Jannsen;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Denedron;.
has a financial relationship (Consultant or Advisor (General Urology)) with Jannsen;.
has a financial relationship (Consultant or Advisor (General Urology)) with Myriad;.
has a financial relationship (Consultant or Advisor (General Urology)) with Clovis;.
has a financial relationship (Consultant or Advisor (General Urology)) with Novartis;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Progenics;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Invitae;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Endocyte;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Theragnostics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Noria Therapeutics Inc.;.

Chandru Sundaram, MD

has a financial relationship (Leadership Position (Robotic Surgery)) with Journal of Endourology;.
has a financial relationship (Leadership Position (Robotic Surgery)) with Endourological Society;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: September, 2021
Expiration Date: September, 2022

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.